<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

What's Next for Immune Checkpoint Inhibitors: TIM-3?

Unlike negative regulators, such as PD-1 and CTLA-4 (which have been proposed as therapeutic targets in different cancer types) the function of TIM-3 (T-cell immunoglobulin and mucin domain 3) in cancer has just begun to be studied and little is known about its role.

TIM Protein Family Involved in Apoptosis

The TIM protein family is composed of three members in humans (hTIM1, 3, and 4) and eight in mice (mTIM1-8). TIM proteins are type-I cell surface glycoproteins composed of a signal peptide, an extracellular IgV domain, a mucin-like domain, a transmembrane domain, and an intracellular cytoplasmic tail.

All members share a conserved sequence homology in the IgV domain, while other domains demonstrate poor homology. The IgV domains of all hTIM proteins contain a high-affinity binding site for PS, a phospholipid constituent of eukaryotic membranes [1, 2].

Generally present on the cytosolic side of the plasma membrane lipid bilayer, upon the onset of apoptosis PS is translocated to the outer leaflet of the plasma membrane, making the cell a target for scavenger receptors on phagocytes [3, 4].

TIM-3 has Both Positive and Negative Regulatory Functions in Immune Response

TIM proteins are also implicated in the regulation of innate and adaptive immune responses. Particularly, TIM-3 is expressed on CD4+ T cells that secrete interferon-gamma (IFN-γ), CD8+ T cells, Treg, and innate immune cells (DC, NK cells, and monocytes). TIM-3 has also been proposed as a regulator of the Th1 type immune response. Evidence suggests TIM-3 has both negative and positive regulatory functions on diverse components of the immune response.

In cancer patients, TIM-3 is upregulated on tumor antigen-specific CD8+ T cells and CD8+ TIL [5-7]. Administration of TIM-3 mAbs increases proliferation and cytokine production by tumor antigen-specific T cells [5-7].

Cancer Cells also Express TIM-3, Associated with Disease Progression and Decreased Survival Times

However, TIM-3 expression is not restricted to mononuclear cells, as it has also been detected expressed on distinct types of cancer cells, for example myeloid leukemia, sarcoma, gastric, cervical, and pulmonary cancer, and osteosarcoma. In many of these types of cancer, the increased expression of TIM-3 has been associated with disease progression and shorter survival.

Preclinical Studies Show Potential of Anti-TIM-3 and Checkpoint Inhibitor Combination Therapy

In preclinical models, TIM-3 has been shown to be upregulated on TIL in mouse tumor models such as the CT-26 colon adenocarcinoma, 4T1 mammary adenocarcinoma, and B16-F10 melanoma models. Administration of TIM-3 mAbs alone had only a modest antitumor effect; however, combination of anti-TIM-3 and anti-PD-1/PD-L1 monoclonal antibodies significantly suppressed tumor growth [7].

Another preclinical study showed that TIM-3 mAb injection slowed tumor progression in many mouse tumor models (e.g. MC38 colon carcinoma, WT3 sarcoma, CT-26 colon adenocarcinoma, and TRAMP-C1 prostate tumor). Furthermore, combinations of TIM-3 mAbs and CTLA-4 mAbs, or TIM-3 mAbs and PD-1 mAbs had a much greater antitumor effect.

These studies both support the potential of blocking TIM-3 in combination with other immune checkpoint inhibitors for cancer treatment [8, 9].

Clinical Development is at an Early Stage

Currently, only two TIM-3 antagonistic monoclonal antibodies are in early-phase clinical development (MBG453 and TSR-022). The safety and efficacy of MGB453 (Novartis, Basel, Switzerland) is being evaluated in the first-in-human, Phase I-Ib/II open-label multi-center study as a single agent and in combination with PD-1 mAbs in adult patients with advanced malignancies (NCT02608268).

TSR-022 (TESARO, Waltham, USA) is currently being evaluated as a single agent again in a first-in-human Phase I trial in patients with advanced solid tumors (NCT02817633), which will move on to explore the safety and clinical activity of TSR-022 as a monotherapy as well as in combination with an anti-PD-1 antibody in patients with selected tumor types.

These trials will be watched with great interest for both safety and efficacy readouts, to see if TIM-3 could be the next big thing in immune checkpoint inhibitors.

References and Further Reading on TIM-3:

  1. Kobayashi et al. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity. 2007;27(6):927-40.
  2. DeKruyff et al. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol. 2010;184(4):1918-30.
  3. Schlegel, Williamson . Phosphatidylserine, a death knell. Cell Death Differ. 2001;8(6):551-63.
  4. Ravichandran. Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. Immunity. 2011;35(4):445-55.
  5. Fourcade, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207(10):2175-86.
  6. Gao et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLOS One. 2012;7(2):e30676.
  7. Sakuishi et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(10):2187-94.
  8. Nirschl et al. Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 2013;19:4917e34.
  9. Ngiow et al. Prospects for TIM-3-targeted antitumour immunotherapy. Cancer Res 2011;71:6567e71.

Related Posts